^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

COMPANY:
Integrated DNA Technologies

i
Other names: Integrated DNA Technologies | Swift Biosciences
Related tests:
Evidence

News

4ms
Volta Labs and Integrated DNA Technologies partner to advance target enrichment workflows (PRNewswire)
"Volta Labs...and Integrated DNA Technologies (IDT)...announced a partnership to further the shared mission of making NGS solutions more accessible...Along with the partnership, Volta Labs will become a member of the IDT Collab Network."
Licensing / partnership
4ms
Integrated DNA Technologies and Element Biosciences accelerate next generation sequencing workflows for Element’s AVITI™ System (Integrated DNA Technologies Press Release)
"Life sciences companies Integrated DNA Technologies (IDT) and Element Biosciences, Inc. have bolstered their partnership with products to enable more efficient and streamlined next generation sequencing (NGS) workflows for users of the AVITI System, an innovative sequencing and multi-omics platform based on Element’s novel avidity base chemistry."
Licensing / partnership
8ms
Tecan sues Qiagen, Invitae, others for patent infringement (Genomeweb)
"Tecan has sued Invitae, ArcherDx, Integrated DNA Technologies, and Qiagen for allegedly infringing on patents related to nucleic acid enrichment and high-throughput sequencing methods...Tecan asserts in the first complaint that its technology underlies what Invitae, ArcherDx, and IDT refer to as their Anchored Multiplex PCR (AMP) target enrichment technology, which is found in Invitae's Personalized Cancer Monitoring (PCM) service and in ArcherDx's LiquidPlex, VariantPlex, and FusionPlex kits."
Patent
|
LiquidPlex™ • Personalized Cancer Monitoring (PCM™)
1year
Jury rules in favor of Natera, finding all asserted patents valid and infringed by ArcherDX/Invitae; awards $19.35 million in past damages for royalties and lost profits (Natera Press Release)
"Natera, Inc...announced that a jury in the U.S. District Court for the District of Delaware has reached a unanimous verdict in favor of Natera in the patent infringement suit it filed against ArcherDX/Invitae Corp. The jury found that all accused ArcherDX/Invitae products infringe three of Natera’s patents."
Corporate lawsuit • Patent
1year
Integrated DNA Technologies launches new Archer™ FUSIONPlex™ Core Solid Tumor Panel for cancer research (Integrated DNA Technologies Press Release)
"Integrated DNA Technologies (IDT)...is supporting research labs worldwide with a new solution to optimize operational efficiency and the identification of solid cancer tumors. The just-launched IDT Archer FUSIONPlex Core Solid Tumor Panel is a first-line cancer research testing solution that has been expanded and optimized for additional single nucleotide variant (SNV) and indel coverage to streamline fusion detection and variant calling through a single assay. The new RNA-based sequencing offering for solid tumors uses a single RNA/TNA input sample and provides a scalable, easy-to-use solution that offers time, resource and cost savings for researchers."
Launch
|
Archer™ FusionPlex™ Core Solid Tumor Panel
over1year
Integrated DNA Technologies Acquires ArcherDX Next Generation Sequencing Research Assays from Invitae Corporation (Integrated DNA Technologies Press Release)
"Integrated DNA Technologies, Inc....announced it closed on the purchase of Next Generation Sequencing (NGS) research assays from Invitae Corporation (NYSE: NVTA) under the trademarked name Archer. The integration of IDT’s portfolio with the acquired NGS research assays—which have been foundational in researching novel cancer fusions—will empower labs with an all-in-one solution to uncover biomarkers and advance cancer discoveries. The transaction enables IDT to expand its existing operations, build upon the legacy Archer portfolio, and welcome more than 100 new associates globally....Transaction Details-IDT purchased Archer NGS research assays—which reported high double-digit growth since 2019—from Invitae for cash consideration of approximately $48 million, subject to certain adjustments. The transaction is structured as an asset deal and includes a license to intellectual property related to the AMP technology."
M&A
|
Archer® FusionPlex® Comprehensive Thyroid & Lung (CTL) Kit • Archer® FusionPlex® Acute Lymphoblastic Leukemia (ALL) • Archer® FusionPlex® Lung Kit • Archer® FusionPlex® Lymphoma • Archer® FusionPlex® Myeloid Kit • Archer® FusionPlex® Oncology Research Kit • Archer® FusionPlex® Sarcoma kit • Archer® VariantPlex® Comprehensive Thyroid and Lung (CTL) kit • Archer® VariantPlex® Myeloid panel • Archer® VariantPlex® Solid Tumor Kit • FusionPlex® Dx • FusionPlex® Pan Solid Tumor v2 panel • FusionPlex™ Heme v2 panel • FusionPlex™ Pan-Heme panel • LiquidPlex™